ClinicalTrials.gg
Not yet recruitingNCT05700266AA-ICASUpdated Dec 21, 2023

Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis

A Phase 2/3 interventional study of Rivaroxaban and Clopidogrel in Ischemic Stroke, Intracranial Atherosclerosis and Stenosis, sponsored by The First Affiliated Hospital with Nanjing Medical University. Not yet recruiting. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-21.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 2/3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,180
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing rivaroxaban in Ischemic Stroke — 4 open to participants now, 4 under way, 2 of them phase 3. Rivaroxaban · Ischemic Stroke.

Planned enrollment
6th of 10
1,180 · median 1,597
Started
2023
the only one that year
Phase 2/3
2 of 10
1 open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
The First Affiliated Hospital with Nanjing Medical University

Among the 10 studies testing rivaroxaban in Ischemic Stroke, this one is the 6th largest by planned enrollment, is the only one that started in 2023, is one of 2 in phase 2/3, and was the 7th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

4 of the 10 studies testing rivaroxaban in Ischemic Stroke are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing rivaroxaban in Ischemic Stroke, or all of them as a file.
02

Study summary

The primary goal of the clinical trial is to test the effect of oral rivaroxaban plus aspirin in patients with recent stroke/ transient ischemic attack (TIA) caused by intracranial artery stenosis. Participants will be divided into 2 groups to receive either oral rivaroxaban plus aspirin or oral clopidogrel plus aspirin. The main question it aims to answer is whether the experimental group (oral rivaroxaban plus aspirin) is superior to the control group ( oral clopidogrel plus aspirin) to lower recurrent stroke/TIA or death in these patients during 1 year of follow-up.

Read the detailed description

Intracranial atherosclerotic stenosis (ICAS) accounts for up to 30-50% of strokes amongst Asian patient cohorts, in contrast to 5-10% of strokes amongst western patient cohorts. The SAMMPRIS established aggressive medical management (dual antiplatelet therapy using asprin and clopidogrel, intensive management of vascular risk factors, and lifestyle modification) as a superior choice for symptomatic ICAS compared to the percutaneous transluminal angioplasty and stenting. However, around 15% still had recurrent stroke or death during a median follow-up of 32.4 months in SAMMPRIS study in the aggressive medical management group.

Rivaroxaban is a Non-vitamin K antagonist oral anticoagulant (NOAC) that Directly and selectively inhibits factor Xa. 2019 European Society of Cardiology (ESC) recommended that adding rivaroxaban (2.5mg twice a day) to aspirin for long-term secondary prevention in patients with chronic coronary syndromes (post-myocardial infarction >1 year) may be considered (IIB). 2020 ESC also recommended the adding of rivaroxaban (2.5mg twice a day for 1 year) to aspirin plus clopidogrel in acute coronary syndrome (IIB).

The proposed study will directly compare rivaroxaban on top of aspirin with clopidogrel on top of asprin for preventing recurrent stroke/TIA and death in recent stroke/TIA patients with ICAS.

The investigators calculated that a sample of 1180 patients (590 in each arm) would provide 80% power to detect a relative risk reduction of 35% in the ravaxaban-aspirin group, with a two-sided type I error of 0.05, assuming an event rate of 15% in the clopidogrel-aspirin group and a 5% overall rate of withdrawal.

Baseline features of the two groups were compared with the use of an independent group t-test (for means) or chi-square test (for percentages). Analysis of primary and secondary outcomes was based on Kaplan-Meier estimates of cumulative incidence. All analyses were performed on an intention-to-treat basis, unless specified otherwise. All tests were two-sided, and a P value of 0.05 was considered to indicate statistical significance. All statistical analyses were performed with the use of SPSS software.

03

Conditions studied

  • Ischemic Stroke
  • Intracranial Atherosclerosis
  • Stenosis

Keywords

  • rivaroxaban, stroke, intracranial atherosclerosis stenosis
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 30 years and ≤ 75 years
  2. or Acute ischemic stroke that occurred within 30 days prior to randomization.
  3. Modified Rankin score of ≤ 3
  4. TIA or Acute ischemic stroke attributed to a 50 to 99% stenosis of a major intracranial artery (internal carotid artery [ICA], vertebral artery [VA], basilar artery [BA] and the M1 segment of middle cerebral artery [MCA]). The diagnostic evaluation for ICAS at each site is confirmed by the local investigator, using magnetic resonance angiography (MRA), or computerized tomographic angiography (CTA), high resolution MR, or digital substraction angiography (DSA).
  5. To increase the likelihood that the symptomatic intracranial stenosis is atherosclerotic, patients aged 30-49 years are required to meet at least one additional criteria (i-vi) below:

    i. insulin dependent diabetes for at least 15 years. ii. at least 2 of the following atherosclerotic risk factors: hypertension (blood pressure ≥ 140/90 or on antihypertensive therapy); dyslipidemia (low density lipoprotein [LDL] ≥ 130 mg /dl or high density lipoprotein [HDL] \< 40 mg/dl or fasting triglycerides ≥150 mg/dl or on lipid lowering therapy); smoking; non-insulin dependent diabetes or insulin dependent diabetes of less than 15 years duration; family history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, stroke, carotid endarterectomy or stenting, peripheral vascular surgery in parent or sibling who was \< 55 years of age for men or \< 65 for women at the time of the event.

    iii. history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or peripheral vascular surgery for atherosclerotic disease.

    iv. any stenosis of an extracranial carotid or vertebral artery, another intracranial artery, subclavian artery, coronary artery, iliac or femoral artery, other lower or upper extremity artery, mesenteric artery, or renal artery that was documented by non-invasive vascular imaging or catheter angiography and is considered atherosclerotic. v. aortic arch atheroma documented by non-invasive vascular imaging or catheter angiography.

    vi. any aortic aneurysm documented by non-invasive vascular imaging or catheter angiography that is considered atherosclerotic.

  6. Patient agrees with follow-up visits and is available by phone.
  7. Patient understands the purpose and requirements of the study, can make him/herself understood, and has signed .

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment of target intracranial lesion with a stent, angioplasty, or other mechanical devices (e.g. mechanical thrombectomy, coil embolization)
  2. Plan to perform angioplasty, stenting, coiling, thrombectomy, endarterectomy or aneurysmal coil embolization for any other cerebral blood vessels (common carotid artery [CCA], ICA, VA, MCA, anterior cerebral artery [ACA], posterior cerebral artery [PCA] et al)
  3. Intracranial tumor (except meningioma) or any intracranial vascular malformation
  4. Thrombolytic therapy within 24 hours prior to randomization
  5. Progressive neurological signs within 24 hours prior to enrollment
  6. History of any intracranial hemorrhage (parenchymal, subarachnoid, subdural, epidural)
  7. Intracranial arterial stenosis due to arterial dissection; MoyaMoya disease; any known vasculitic disease; viral vasculopathy; neurosyphilis; any other intracranial infection; any intracranial stenosis associated with cerebral spinal fluid pleocytosis; radiation induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; benign angiopathy of central nervous system; postpartum angiopathy; suspected vasospastic process; reversible cerebral vasoconstriction syndrome (RCVS); suspected recanalized embolus
  8. Presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within three months, dilated cardiomyopathy, left atrial spontaneous echo contrast, less than 30%
  9. Known allergy or to aspirin, clopidogrel or rivaroxaban.
  10. Active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding diathesis, \< 100,000, hematocrit \< 30, international normalized ration [] > 1.5, clotting factor abnormality that increases the risk of bleeding, current alcohol or substance abuse, uncontrolled severe hypertension (systolic pressure > 180 mm Hg or diastolic pressure > 115 mm Hg), severe liver impairment ( [AST] or alanine transaminase [ALT] > 3 x normal, cirrhosis), creatinine > 3.0 (unless on dialysis)
  11. Major surgery (including open femoral, aortic, cardiac or carotid surgery) within previous 30 days or planned in the next 1 year after enrollment.
  12. Any condition other than intracranial arterial stenosis that requires the subject to take any antithrombotic medication other than aspirin (NOTE: exceptions allowed for use of subcutaneous heparin for deep vein thrombosis (DVT) prophylaxis while hospitalized)
  13. Severe neurological deficit that renders the patient incapable of living independently
  14. Dementia or psychiatric problem that prevents the patient from relevant evaluation or follow-up reliably
  15. Co-morbid conditions that may limit survival to less than 1 year
  16. Currently breastfeeding, pregnancy or of and unwilling to use for the duration of this study
  17. Enrollment in another study that would conflict with the current study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,180 participants (estimated)

Study arms

  • Experimental
    Rivaroxaban and Aspirin

    Rivaroxaban (2.5mg orally twice a day for 90 days) and Aspirin (100mg once a day for 1 year)

    Drug: Rivaroxaban · Drug: Aspirin · Other: Risk Factor Management in both arms

  • Active comparator
    Clopidogrel and Aspirin

    Clopidogrel (300mg loading dose, then 75mg once daily for 90 days) and Aspirin (100mg once a day for 1 year)

    Drug: Clopidogrel · Drug: Aspirin · Other: Risk Factor Management in both arms

Interventions

  • Rivaroxaban (2.5mg orally twice a day for 90 days)

  • Clopidogrel (300mg loading dose, then 75mg once daily for 90 days)

  • Aspirin (100mg once a day for 1 year)

  • OtherRisk Factor Management in both arms

    Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed

06

What researchers measure

Primary outcomes

  1. any stroke (ischemic or hemorrhagic) or death during 1 year of follow-up

    Time frame: the primary outcome will be assessed during 1 year of follow-up after recruitments.

Secondary outcomes

  1. Changes in the neurological function recovery

    Neurological function will be evaluated using National Institute of Health stroke scale (NIHSS), modified Ranking Scale.

    Time frame: Neurological function will be evaluated at 90 days, 6 months and 1 year after recruitments.

  2. Major non-intracranial bleeding

    Major non-intracranial bleeding is defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria: clinically overt bleeding with a fatal outcome, a reduction in haemoglobin level of ≥20 g/l within 7 days, transfusion of at least two units of blood, or symptomatic bleeding in a critical area or organ (intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal).

    Time frame: during 1 year of follow-up after recruitments.

  3. Clinically relevant non-major bleeding

    Clinically relevant non-major bleeding is defined as bleeding not fulfilling the ISTH criteria, but that was clinically overt and led to hospitalization, change of antithrombotic therapy, or necessitated a medical or surgical intervention.

    Time frame: during 1 year of follow-up after recruitments.

  4. acute myocardial infarction,acute limb ischemia

    Time frame: during 1 year of follow-up after recruitments.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data will be available to other researchers under reasonable request and approved by the ethics committee.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2023; primary completion for Dec 2024, 12 months later.

Of 31 phase 2/3 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 55. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2022
First posted
Jan 26, 2023
StartEst.
Dec 30, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Dec 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05700266
Collaborators
National Natural Science Foundation of China
Responsible party
Kezhong Zhang (Professor, The First Affiliated Hospital with Nanjing Medical University) — Principal investigator
First posted
Jan 26, 2023
Start date
Dec 30, 2023 (estimated)
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Dec 21, 2023

Study contacts

Zhaolu Wang, Doctor
Contact
wangzhaolu123@163.com
+86-18100613663
Kezhong Zhang, Doctor
Contact
zhangkezhong8@126.com
+86-13770840575
Kezhong Zhang, Doctor
study chair · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion